Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study
- PMID: 15050905
- DOI: 10.1016/j.bone.2003.12.021
Two to three years of hormone replacement treatment in healthy women have long-term preventive effects on bone mass and osteoporotic fractures: the PERF study
Abstract
Hormone replacement therapy (HRT) is often prescribed for a few years to suppress menopausal symptoms. Although its long-term use of HRT for the primary prevention of osteoporosis is not currently recommended, the long-term skeletal benefits of the limited therapy are of great interest. To determine whether administration of HRT for 2-3 years in the early postmenopausal years provides long-term benefits, such as prevention of bone loss and osteoporotic fractures, we studied a group of 347 healthy postmenopausal women with normal bone mass who had earlier completed one of four placebo-controlled HRT trials and who were reexamined 5, 11, or 15 years after stopping HRT. Of these women, 263 received either HRT or placebo for 2-3 years with no further bone-sparing treatment until follow-up, and the remaining 84 women reported either prolonged or current use of HRT at reexamination. Bone mineral density (BMD) at the spine (L1-L4) and bone mineral content (BMC) in the forearm were measured at baseline, the end of the trials, and follow-up. At follow-up, we assessed the radiological presence of vertebral fracture and collected information on the new incidence of nonvertebral fractures. Compared with that of the placebo-treated women, the BMD and BMC of HRT-treated women continued to show significantly higher values (>5%) even many years after stopping HRT. After stopping treatment, the rate of bone loss returned to normal postmenopausal rates. The preservation of bone mass in the HRT group was accompanied by a significantly reduced risk of all osteoporotic fractures as compared with the placebo group [OR = 0.48 (95% CI, 0.26-0.88)]. 'Fast losers' on placebo had more than a 4-fold higher risk of fractures than had the women on limited HRT with a normal rate of bone loss after withdrawal. In conclusion, limited HRT administered in the early postmenopausal years offers long-lasting benefits for the prevention of postmenopausal bone loss and osteoporotic fracture.
Similar articles
-
Recency and duration of postmenopausal hormone therapy: effects on bone mineral density and fracture risk in the National Osteoporosis Risk Assessment (NORA) study.Menopause. 2003 Sep-Oct;10(5):412-9. doi: 10.1097/01.GME.0000086467.82759.DA. Menopause. 2003. PMID: 14501602
-
[Postmenopausal hormonal treatment: conventional hormone replacement therapy or tibolone? Effects on bone].J Gynecol Obstet Biol Reprod (Paris). 2002 Oct;31(6):541-9. J Gynecol Obstet Biol Reprod (Paris). 2002. PMID: 12407324 Review. French.
-
[The influence of hormonal replacement therapy on bone density in postmenopausal women depending on polymorphism of vitamin D receptor (VDR) and estrogen receptor (ER) genes].Ann Acad Med Stetin. 2003;49:111-30. Ann Acad Med Stetin. 2003. PMID: 15552843 Clinical Trial. Polish.
-
Parathyroid hormone added to established hormone therapy: effects on vertebral fracture and maintenance of bone mass after parathyroid hormone withdrawal.J Bone Miner Res. 2001 May;16(5):925-31. doi: 10.1359/jbmr.2001.16.5.925. J Bone Miner Res. 2001. PMID: 11341338 Clinical Trial.
-
Postmenopausal osteoporosis and hormone replacement therapy.Minerva Med. 2004 Dec;95(6):507-20. Minerva Med. 2004. PMID: 15785435 Review. English, Italian.
Cited by
-
Long-term consequences of estrogens administered in midlife on female cognitive aging.Horm Behav. 2015 Aug;74:77-85. doi: 10.1016/j.yhbeh.2015.04.012. Epub 2015 Apr 25. Horm Behav. 2015. PMID: 25917862 Free PMC article. Review.
-
European guidance for the diagnosis and management of osteoporosis in postmenopausal women.Osteoporos Int. 2013 Jan;24(1):23-57. doi: 10.1007/s00198-012-2074-y. Epub 2012 Oct 19. Osteoporos Int. 2013. PMID: 23079689 Free PMC article.
-
Antiosteoporosis therapy after discontinuation of menopausal hormone therapy: a systematic review.Hormones (Athens). 2024 Jun;23(2):339-344. doi: 10.1007/s42000-024-00526-1. Epub 2024 Jan 18. Hormones (Athens). 2024. PMID: 38236381 Free PMC article.
-
Estrogen and bones after menopause: a reappraisal of data and future perspectives.Hormones (Athens). 2021 Mar;20(1):13-21. doi: 10.1007/s42000-020-00218-6. Epub 2020 Jun 9. Hormones (Athens). 2021. PMID: 32519298 Review.
-
Perioperative risk factors for osteoporosis after radical gastrectomy for gastric cancer.BMC Surg. 2024 Dec 27;24(1):420. doi: 10.1186/s12893-024-02717-4. BMC Surg. 2024. PMID: 39731108 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical